Gregory Michael Lubiniecki, MD
Dr. Gregory Michael Lubiniecki is a medical oncologist who specializes in treating patients with lung cancer and malignant pleural mesothelioma at Temple Health’s Fox Chase Cancer Center in Philadelphia, Pennsylvania. Though he left full-time practice to accept a role overseeing cancer research at Merck & Company, he believes it is important both personally and professionally to continue having a one-on-one connection with patients, and continues holding a clinic at Fox Chase once a week.[1]
Dr. Lubiniecki’s passion for oncology care was motivated by his family’s experience with cancer, watching his mother endure surgery and chemotherapy during his high school years. He is also fascinated by the complexity of the molecular biology involved in cancer.[1]
Education and Career
Dr. Lubiniecki earned his medical degree at Johns Hopkins University in Baltimore, Maryland. He then completed his internship and residency in Internal Medicine at the Mayo Graduate School of Medicine in Rochester, Minnesota, and a fellowship in Hematology and Oncology at the University of Pennsylvania Health System.[1]
After completing his medical education and training, Dr. Lubiniecki worked for the Clinical Practices of the University of Pennsylvania as a medical oncologist, then joined the Fox Chase Cancer Center of Temple Health. Though he joined Merck & Co. as Vice President of Oncology Clinical Research, he continues to volunteer his clinical services at Fox Chase Cancer Center, seeing patients at a clinic he hosts there once a week.[2]
Professional Memberships and Activities
Dr. Lubiniecki is a member of several professional medical societies and organizations, including:[1]
- American College of Physicians
- American Society of Internal Medicine
- American Medical Association
- American Society of Clinical Oncology
- American Society of Hematology
- International Association for the Study of Lung Cancer
- Pennsylvania Medical Society
Research
In addition to his clinical role at Fox Chase Cancer Center, Dr. Lubiniecki is the Vice President of Oncology Clinical Research at Merck & Co. In that role, he leads and oversees cancer research. Dr. Lubiniecki says that the science around cancer treatment is going in an exciting direction, with a focus on modulating the immune system, using cell-based therapies, and targeted delivery. He believes that the patient experience must be considered in the design of every clinical trial.[2]
Some of Dr. Lubiniecki’s recent research led to the following articles, published in respected medical journals:[3]
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Matthew H. Taylor, Emmett V. Schmidt, Corina E. Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi, Gregory M. Lubiniecki, Drew W. Rasco>; Future Oncology. 2021 Feb 1
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non-‒Non-Small-Cell Lung Cancer in the KEYNOTE-010 S… Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Jose Luis Perez-Gracia, Ji Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin Forster, Isabelle Mo…>; Journal of Clinical Oncology. 2020 Feb 20
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, op… Tony Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, Hande Turna, Gilberto de Castro, Vichien Srimuninnimit, Konstantin Laktionov, Igor Bondarenko…> ;Lancet. 2019 May 4
